Parity in Correlation with Stage and Estrogen Receptor Type in Breast Cancer.

Q4 Medicine Kurume Medical Journal Pub Date : 2023-07-03 DOI:10.2739/kurumemedj.MS682013
Ali Abdul Hussein S Al-Janabi
{"title":"Parity in Correlation with Stage and Estrogen Receptor Type in Breast Cancer.","authors":"Ali Abdul Hussein S Al-Janabi","doi":"10.2739/kurumemedj.MS682013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Parity is related to breast cancer in various ways. Its effects on the development of breast cancer are not independent and should be investigated at the same time as other reproductive factors. The association between parity and stage and type of breast cancer receptor was studied.</p><p><strong>Methods: </strong>Parity was established for 75 patients with estrogen receptor (ER) positive breast cancer and 45 patients with ER-negative breast cancer. The stages of breast cancer were also determined.</p><p><strong>Results: </strong>Breast cancer was found to have an association with high parity (≥ 3 parities). Significantly, most patients were diagnosed with stage II breast cancer, and this was especially frequent in patients with high parity. Stage IIB was most common, particularly among those 40-49 years old. ER-positive and ER-negative stage II breast cancer were both common among patients with high parity.</p><p><strong>Conclusion: </strong>Breast cancer, particularly at stage II, is associated with high parity. Parity is also associated with type of breast cancer, based on estrogen receptor category. This finding supports the recommendation that breast cancer should be screened in women with a high parity. Increased births should be considered a risk factor particularly for stage II breast cancer independent of cancer type.</p>","PeriodicalId":39559,"journal":{"name":"Kurume Medical Journal","volume":"68 2","pages":"121-128"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kurume Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2739/kurumemedj.MS682013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Parity is related to breast cancer in various ways. Its effects on the development of breast cancer are not independent and should be investigated at the same time as other reproductive factors. The association between parity and stage and type of breast cancer receptor was studied.

Methods: Parity was established for 75 patients with estrogen receptor (ER) positive breast cancer and 45 patients with ER-negative breast cancer. The stages of breast cancer were also determined.

Results: Breast cancer was found to have an association with high parity (≥ 3 parities). Significantly, most patients were diagnosed with stage II breast cancer, and this was especially frequent in patients with high parity. Stage IIB was most common, particularly among those 40-49 years old. ER-positive and ER-negative stage II breast cancer were both common among patients with high parity.

Conclusion: Breast cancer, particularly at stage II, is associated with high parity. Parity is also associated with type of breast cancer, based on estrogen receptor category. This finding supports the recommendation that breast cancer should be screened in women with a high parity. Increased births should be considered a risk factor particularly for stage II breast cancer independent of cancer type.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌胎次与分期及雌激素受体类型的关系。
背景:胎次与乳腺癌有多种关系。它对乳腺癌发展的影响并不是独立的,应该与其他生殖因素同时进行研究。研究了胎次与分期和乳腺癌受体类型之间的关系。方法:对75例雌激素受体(ER)阳性乳腺癌患者和45例ER阴性乳腺癌患者建立胎次。乳腺癌的分期也被确定。结果:发现乳腺癌与高胎次(≥3胎次)相关。值得注意的是,大多数患者被诊断为II期乳腺癌,这在高胎次患者中尤为常见。IIB期最常见,尤其是在40-49岁的人群中。雌激素受体阳性和雌激素受体阴性的II期乳腺癌在高胎次患者中都很常见。结论:乳腺癌,特别是II期,与高胎次有关。根据雌激素受体的种类,胎次也与乳腺癌的类型有关。这一发现支持了对高胎次女性进行乳腺癌筛查的建议。无论癌症类型如何,增加的出生率都应该被认为是一个危险因素,特别是对于II期乳腺癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Kurume Medical Journal
Kurume Medical Journal Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
33
期刊最新文献
A Case of Sarcoid Reaction in Subcarinal Lymph Node in A Postoperative Breast Cancer Diagnosed by Thoracoscopic Biopsy. Comminuted Transverse Femoral Shaft Fractures Are at Risk for Nonunion. High Expression of NDRG1 is a Poor Prognostic Factor in Patients with Endometrial Endometrioid Carcinoma with Long-Term Observation. Histological Improvement of Hepatic Fibrosis of Decompensated Liver Cirrhosis after Prednisolone and Azathioprine Treatment in a Patient with Autoimmune Hepatitis. Surgical Treatment of Simultaneous Common Femoral and Profunda Femoris Artery Aneurysms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1